FDA says 'not yet' on Lilly's once-weekly Byetta

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. will have to wait a little longer before selling a once-weekly version of its diabetes drug Byetta.

The U.S. Food and Drug Administration told Lilly and its development partners on Byetta that it wants feedback on the new product’s label, clarification of its manufacturing processes and submission of a Risk Evaluation and Mitigation Strategy.

Lilly and San Diego-based Amylin Pharmaceuticals Inc., said they will respond in the next few weeks. They plan to sell the drug under the brand name Bydureon.

But significantly, the FDA said it would require no further testing of Bydureon, which would have threatened to delay its launch much longer.

"In this scenario, we'd anticipate a second-quarter resubmission and a fourth-quarter approval," JPMorgan analyst Cory Kasimov wrote in a research note, according to Reuters.

The drug approval is key for both companies. Byetta, taken as a twice daily injection, has been successful for controlling blood sugar levels in patients and helping some lose weight. It racked up $797 million in worldwide sales last year.

But analysts expect a once-weekly injection of Bydureon to be far more attractive because of its convenience. Analysts expect sales of Bydureon to reach as high as $2 billion by 2015.

Lilly and Amylin’s chances of approval were judged high after the FDA in January approved a similar drug, Victoza, a once-daily injection made by Denmark-based Novo Nordisk A/S.

Bydureon uses technology from Massachusetts-based Alkermes Inc. to release the compound exenatide at a controlled rate.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ